Universal DX (UDX) Closes Series B Funding for Clinical Trials on Colorectal Cancer Screening Blood Test, Signal-C®

Choate represented Universal DX (UDX) in IP diligence for its Series B funding round. This funding advances the clinical trial of Signal-C, UDX’s colorectal cancer screening blood test, which is on track to enroll 15,000 patients across 100 sites. The funding is an extension of the $70M Series B round that UDX closed in November 2023. In addition to the IP diligence, Choate manages UDX's patent portfolio.